Becton Dickinson (BDX) Reports In-Line Q4 EPS, Revenues Beat; Offers FY19 EPS Outlook Below Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. HOOD
9. MU
10. IBM

Go back to Becton Dickinson (BDX) Reports In-Line Q4 EPS, Revenues Beat; Offers FY19 EPS Outlook Below Consensus

Becton Dickinson (BDX) Highlights Clinical Trial Data for LUTONIX 014 Drug-Coated Balloon Below-the-Knee IDE

November 7, 2018 1:14 PM EST

BD (NYSE: BDX) today announced the safety and efficacy data from the LUTONIX® Drug-Coated Balloon (DCB) IDE, level 1 clinical trial for a below-the-knee (BTK) indication.

The clinical study is a prospective, global, multicenter, randomized, controlled trial comparing the LUTONIX® 014 DCB to standard angioplasty for the treatment of narrowed or obstructed... More